1. Home
  2. MRKR vs PTLE Comparison

MRKR vs PTLE Comparison

Compare MRKR & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • PTLE
  • Stock Information
  • Founded
  • MRKR N/A
  • PTLE 2013
  • Country
  • MRKR United States
  • PTLE Singapore
  • Employees
  • MRKR N/A
  • PTLE N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • PTLE Oil Refining/Marketing
  • Sector
  • MRKR Health Care
  • PTLE Energy
  • Exchange
  • MRKR Nasdaq
  • PTLE Nasdaq
  • Market Cap
  • MRKR 19.1M
  • PTLE 16.4M
  • IPO Year
  • MRKR N/A
  • PTLE 2024
  • Fundamental
  • Price
  • MRKR $1.71
  • PTLE $0.22
  • Analyst Decision
  • MRKR Strong Buy
  • PTLE
  • Analyst Count
  • MRKR 3
  • PTLE 0
  • Target Price
  • MRKR $13.17
  • PTLE N/A
  • AVG Volume (30 Days)
  • MRKR 102.6K
  • PTLE 26.4M
  • Earning Date
  • MRKR 08-13-2025
  • PTLE 02-21-2025
  • Dividend Yield
  • MRKR N/A
  • PTLE N/A
  • EPS Growth
  • MRKR N/A
  • PTLE N/A
  • EPS
  • MRKR N/A
  • PTLE N/A
  • Revenue
  • MRKR $5,696,123.00
  • PTLE $98,133,646.00
  • Revenue This Year
  • MRKR N/A
  • PTLE N/A
  • Revenue Next Year
  • MRKR $11.28
  • PTLE N/A
  • P/E Ratio
  • MRKR N/A
  • PTLE N/A
  • Revenue Growth
  • MRKR 71.53
  • PTLE N/A
  • 52 Week Low
  • MRKR $0.95
  • PTLE $0.17
  • 52 Week High
  • MRKR $5.99
  • PTLE $15.78
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 60.22
  • PTLE N/A
  • Support Level
  • MRKR $1.56
  • PTLE N/A
  • Resistance Level
  • MRKR $1.93
  • PTLE N/A
  • Average True Range (ATR)
  • MRKR 0.10
  • PTLE 0.00
  • MACD
  • MRKR 0.02
  • PTLE 0.00
  • Stochastic Oscillator
  • MRKR 57.69
  • PTLE 0.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

Share on Social Networks: